Purpose: As changes in antibiotic therapy are common, intent-to-treat and definitive therapy exposure definitions in infectious disease clinical trials and observational studies may not accurately reflect all antibiotics received over the course of the infection. Therefore, we sought to describe changes in antibiotic therapy and unique treatment patterns among patients with bacteremia. bacteremia admissions with changes in therapy, 95 had unique antibiotic treatment patterns. These findings were consistent in both populations, over time, and among different facilities within study populations. The median time to first therapy change was 2 days after initial therapy, with a median of three changes.
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| INTRODUCTION
Serious infections, such as drug-resistant bloodstream infections, have become increasingly complicated to treat. 1, 2 Initial treatment decisions are often made without knowledge of the infecting organism(s) and in the absence of a confirmed source of infection. 1 Management of these patients is challenging as bloodstream infections are associated with high mortality rates, and evidence suggests that immediate treatment with appropriate therapies can significantly improve survival. 1, 3, 4 However, further complicating these decisions are the lack of real-world evidence regarding the most effective and safe treatment approaches, including which antibiotics to use and their duration of use. 5, 6 The complex treatment regimens used to treat infectious diseases, which consist of relatively short exposure periods and multiple changes in therapy, create great difficulty in accurately defining antibiotic exposures for the evaluation of clinical success. Often, patients are started on empiric broad-spectrum antibiotics for a suspected infection. 1, 7 This therapy may be continued for 1 to 5 days, depending on whether rapid diagnostics are available, when clinical culture results are received, and if/when infectious disease clinicians become involved. Once culture results are available, patients should be switched to targeted or definitive therapy based on the infecting organism and related susceptibilities. 8 However, some may be continued on broad-spectrum therapy. Other changes may be made in preparation for hospital discharge, where intravenous therapy is switched to oral therapy, or cases of insufficient clinical response. Combination therapy regimens further complicate efforts to measure antimicrobial exposures due to potential additive or synergistic effects. As the spectrum of common antibiotic regimens and real-world patterns of treatment for serious infections have yet to be described, the objective of this study was to map all antibiotic exposures for those with bacteremia. As treatment practices may vary by health system, we included both Veterans Affairs (VA) Medical Centers (VAMCs) and community hospitals in our study. Further, treatment practices will vary by causative organism; therefore, we included both an organism-specific cohort and a disease-state cohort.
| METHODS
We utilized two data sources for this retrospective cohort study, the one or more therapies were held for a single day and resumed the following day, and wider dosing frequencies (ie, every 48 h). As such, holds, extended dosing, and 1-day gaps were not counted as changes in therapy in this sensitivity analysis. In the second sensitivity analysis, unique patterns were assessed only for antibiotic exposures and did not account for days of therapy that allowed us to assess treatment strategies rather than day-specific patterns.
As heterogeneity of antibiotic treatments for bacteremia may vary by length of stay, mortality, infection source, and causative organism, we conducted several stratified analyses. For example, we would expect greater homogeneity in treatment patterns during shorter hospital stays, as well as with specific infection sources or causative organisms, whereas heterogeneity may be greater among those who die during the admission. We therefore assessed unique antibiotic treatment patterns stratified by length of stay, osteomyelitis (VA population only and diagnosis code present during the admission), inpatient mortality, and methicillin susceptibility of S aureus (VA population only). 7 Length of stay was stratified at 7 days and also by median length of stay in each setting (Table 1) .
| RESULTS
We identified 50 467 bacteremia admissions (47 584 VA, 2883
Optum-Premier; Table 1 ). The VA population was older (median age 64 versus 58 y) and mostly male (97.7% versus 51.2%) compared with the Optum-Premier population. Further, the VA population had a greater comorbidity burden (median Charlson comorbidity index 3 versus 2), longer length of stay (median 11 versus 5 d), and higher inpatient mortality rate (17.9% versus 6.6%).
Rates of therapy changes were similar in both populations as shown in Table 1 
KEY POINTS
• Among more than 50 000 bacteremia admissions, antibiotic treatment was highly heterogeneous in two distinct study populations, over time, and among different facilities within each study population.
• Changes in antibiotic therapy occurred in 89% of admissions (median of three changes over course of treatment), with 95% having unique treatment patterns.
• Common antibiotic exposure definitions of intent-totreat and definitive therapy would misclassify exposure in 86% of the study population, which highlights the need for better operational definitions of exposure in infectious diseases research.
while ceftriaxone (28.3%) was the most common antibiotic in the Optum-Premier population ( Figure 5 ). 10 The second most common antibiotic was piperacillin-tazobactam in the VA population (22.5%) and vancomycin (20.2%) in the Optum-Premier population.
Common treatment patterns among admissions both with and without changes in therapy differed between the study populations.
The top 250 treatment patterns (sorted by count, then alphabetically)
for each population, with at least four observations per pattern, can be found in Tables S1.1 (Table S1 .2). In OptumPremier, the top 10 patterns included seven different antibiotics (Table S1. 3). Monotherapy, with either vancomycin or levofloxacin, was the common treatment observed among those without changes in therapy (Table S1 .4). Duration of antibiotic therapy was 4 days or less among the top five patterns in each population (Tables S1.1-S1.4). While changes in therapy were slightly lower when accounting for holds, extended dosing, and 1-day gaps (Table S1 .5; 87.5% VA, 84.5% Optum-Premier), proportions of unique patterns were similar (93.9% VA, 97.0% Optum-Premier).
In stratified analyses by length of stay, heterogeneity was lower in shorter hospital stays, although it still exceeded 70% in shorter stays and was greater than 90% in longer stays (Tables S1.6-S1.7;
≤ median length of stay as noted in (Table S2 .9; 92.7%).
| DISCUSSION
To our knowledge, this is the first study to describe the full spectrum of real-world treatment patterns for bacteremia in two national cohorts. Exposure mapping has traditionally been applied in adherence research, specifically to long-term treatments for chronic diseases, such as diabetes or hypercholesterolemia. 11 By creating drug treatment maps for each patient on each day of the observation period, adherence research is able to calculate exposure measures such as proportion of days covered, medication possession ratio, and gaps in therapy. 11, 12 Using this approach, we were able to identify changes in antibiotic therapy and unique patterns of antibiotic treatments. we expected a change in unique patterns; however, heterogeneity remained stable in subsequent years. 7 When considering unique patterns collectively among those with and without changes in therapy, variability exceeded 90% even among the facilities with the lowest percentage of unique patterns.
We did expect to observe greater homogeneity in treatment patterns in the VA study population for three reasons: (1) We included admissions with a specific infection type (bacteremia)
caused by a specific organism (S aureus) that was confirmed from positive blood cultures, (2) these were admissions from a closed health care system, and (3) the study population tends to be more homogenous in terms of patient characteristics. We also expected to observe greater heterogeneity in the Optum-Premier population since we included admissions with diagnoses of bacteremia caused by any organism. While heterogeneity could be interpreted as higher than expected in the VA and perhaps lower than expected in Optum-Premier, heterogeneity was high in both groups (86.3% VA, 88.6% Optum-Premier).
Total duration of antibiotic exposure was low among the common patterns, indicating that these common patterns were observed among patients who were discharged soon after culture/admission.
We did not assess postdischarge outpatient antibiotic treatments as we were specifically interested in inpatient treatment patterns. Had we included the full duration of treatment, which would have been a minimum of 2 weeks for S aureus bacteremia and may include postdischarge changes to oral or outpatient parenteral antibiotic therapy to facilitate hospital discharge, heterogeneity likely would have been even greater. 7 Further, in assessing treatment strategies that did not account for days of therapy, heterogeneity still exceeded 70%. Interestingly, heterogeneity remained high in shorter hospital stays, exceeding 70%, by inpatient mortality and methicillin susceptibility, exceeding 80% in all groups, and in a single infection source (osteomyelitis), exceeding 90%. Although we expected heterogeneity 21, 24 A solution to this misclassification has been to include those without changes in therapy, treated with monotherapy or simple combinations. However, as our study demonstrates, these patterns are uncommon in real-world clinical practice.
As re-evaluation of antibiotic therapy is a core element of antimicrobial stewardship, we expected to see high rates of therapy changes. 8 However, we did not expect such extensive heterogeneity in real-world treatment patterns. It is unclear whether the variability in treatment approaches for the same infection represents the forefront of individualized medicine, where each host-organism relationship is unique and requires a distinct approach to treatment, or, alternatively, whether the variability results from a lack of quality evidence supporting specific treatment regimens, particularly specific antibiotics for specific durations.
To avoid inaccurate exposure definitions in infectious disease research, there are several solutions for handling these traditionally ignored exposure periods. First, clinical trials could be designed so that randomization accounts for empiric therapy. Second, sensitivity analyses could be conducted in clinical trials and observational studies that control for differences in empiric therapy prior to randomization/definitive therapy, as well as differences in antibiotic exposures after randomization/definitive therapy. Third, time-varying methods could be used to account for both time-varying antibiotic exposures and time-varying outcomes. Fourth, highly specific operational exposure definitions could be used in observational research, where study populations are restricted to patients with similar exposure patterns as identified from daily exposure mapping. The addition of any of these approaches would provide a more accurate description of the relationship between treatment and the clinical outcomes being assessed.
| LIMITATIONS
The main limitation of the study was the use of diagnosis codes to identify bacteremia in the Optum-Premier population. Treatment patterns will vary by causative organism; however, microbiology data
were not available from the data source. Bacteremia diagnosis codes have demonstrated varying sensitivity and positive predictive value for positive blood cultures. 25 However, we observed similar heterogeneity in prescribing patterns and related implications on characterizing treatment effects between our culture-confirmed bacteremia population and the population identified from diagnosis codes. Second, we did not assess antibiotic dose. Had we included dose, we expect that variability in antibiotic patterns would be close to 100%. Third, we did not exclude patients with concomitant infections, and therefore, some of the antibiotic exposures may have been targeting other infecting organisms. Fourth, we did not evaluate heterogeneity in treatment patterns by patient characteristics, such as age and comorbidity burden. However, since heterogeneity was high in the overall populations, it would have also been within patient subgroups. Lastly, we did not assess postdischarge antibiotic treatments. Therefore, if a switch to oral therapy occurred prior to discharge, it was captured in the pattern. However, if the prescription was dispensed after the discharge date, it was not captured as part of the pattern. The generalizability of this study is limited to the two national cohorts included, patients admitted to VAMCs and patients from the Optum Clinformatics database admitted to Premier community hospitals.
| CONCLUSIONS
Changes in antibiotic therapy for bloodstream infections were nearly universal in both VAMCs and community hospitals. Common treatment approaches, consisting of homogenous (nonunique) treatment patterns, were used in only 14% of bacteremia admissions. This heterogeneity in antibiotic treatment patterns was consistent over time and was similar among different facilities within each study population. Our findings highlight the challenges of evidence-based research for the treatment of infectious diseases. Since so few patients receive the same regimen, true head-to-head comparisons may not be possible due to small numbers and therefore rely on overly broad definitions. As antibiotic exposure definitions are unlikely to be as accurate as previously assumed, noninferiority, superiority, comparative effectiveness, and comparative safety studies in infectious diseases should be interpreted with caution. 
ETHICS STATEMENT
